Global Poxviridae Infections Drug Market Size By Type (CJ-40011, 24a), By Application (Hospital, Clinic), By Region, And Segment Forecasts, 2023 to 2032

The Global Poxviridae Infections Drug Market was valued at USD 1.1 billion in 2023 and is projected to reach USD 2.3 billion by 2031, expanding at a CAGR of 9.5% from 2023 to 2031. The market growth is driven by rising incidences of monkeypox and smallpox re-emergence concerns, expanding government stockpiles for bioterrorism preparedness, and advances in antiviral therapeutics targeting poxviruses. Public health surveillance and global investments in infectious disease preparedness are accelerating drug development and procurement, especially post-COVID-19, spotlighting the need for effective antiviral treatments for viral families like Poxviridae.

Drivers:

1. Rising Cases of Monkeypox and Orthopoxvirus Infections: The global resurgence of monkeypox in non-endemic regions has emphasized the necessity for effective antiviral drugs. Increased human-to-human transmission, coupled with zoonotic outbreaks, has propelled research and demand for treatments.

2. Government Initiatives for Biodefense: National stockpiling of smallpox antivirals (like Tecovirimat) in response to bioterrorism threats is driving the market. The U.S. FDA and other regulatory bodies have accelerated drug approvals under emergency preparedness strategies.

3. Advancements in Antiviral Drug Development: Innovations in nucleoside analogs, host-targeted therapies, and viral replication inhibitors have enhanced treatment efficacy. Pipeline drugs are increasingly targeting broad-spectrum orthopoxvirus activity.

Restraints:

1. Limited Commercial Profitability: The market is heavily reliant on government procurement programs and has limited commercial use, which reduces private sector interest in R&D.

2. Regulatory Hurdles for Rare Infectious Diseases: The rarity and sporadic nature of outbreaks pose challenges in conducting large-scale clinical trials, delaying drug approval timelines.

Opportunity:

1. Expansion of Global Pandemic Preparedness Programs: Global health organizations are expanding disease preparedness initiatives, increasing funding for stockpiling antivirals against future pandemics.

2. Increased R&D Collaboration in Emerging Markets: Partnerships among biotech firms, academic institutions, and governments in regions like Asia-Pacific and Latin America present untapped opportunities for market entry and clinical trial expansion.

Market by System Type Insights:

Based on system type, Antiviral Drugs dominated the market in 2023, led by FDA-approved agents like Tecovirimat and Cidofovir. Tecovirimat, in particular, is the first antiviral specifically indicated for smallpox and has shown efficacy against monkeypox. The pipeline is increasingly populated with broad-spectrum antivirals showing promising results in early-phase trials.

Market by End-use Insights:

In terms of end-use, Government Agencies & Biodefense Programs held the largest market share in 2023, accounting for over 60%. Strategic national stockpiles and emergency use authorizations (EUAs) remain key drivers. Meanwhile, the Hospital and Specialty Clinics segment is projected to grow rapidly due to increased hospitalization and treatment during monkeypox outbreaks.

Market by Regional Insights:

North America emerged as the leading region in 2023, driven by high public health funding, early adoption of poxvirus therapeutics, and robust regulatory support. However, Asia-Pacific is expected to witness the highest CAGR during the forecast period, fueled by rising outbreak surveillance, infrastructure investments, and growing clinical trial activity in India and China.

Competitive Scenario:

Major players in the Global Poxviridae Infections Drug Market include:

SIGA Technologies, Inc.

Chimerix, Inc.

Emergent BioSolutions

Tonix Pharmaceuticals

BioFactura, Inc.

Bavarian Nordic

Gilead Sciences, Inc.

These companies are actively engaged in collaborations with BARDA, NIH, and the WHO to develop and supply poxvirus therapeutics. Notable developments include:

2023: SIGA Technologies expanded global access agreements for Tecovirimat across African countries affected by monkeypox.

2024: Chimerix advanced its dual-action antiviral CMX001 (Brincidofovir) to Phase III trials for multiple orthopoxvirus infections.

2025: Emergent BioSolutions signed a multi-year contract with the U.S. Department of Health and Human Services to expand strategic stockpile inventory.

Scope of Work – Global Poxviridae Infections Drug Market

Report Metric Details

Market Size (2023) USD 1.1 Billion

Projected Market Size (2031) USD 2.3 Billion

CAGR (2023-2031) 9.5%

Market Segments By Drug Type (Antivirals, Vaccines), By End-use (Hospitals, Government Agencies), By Region

Growth Drivers Rise in Monkeypox Cases, Biodefense Funding, Drug Innovation

Opportunities Pandemic Preparedness, Asia-Pacific Expansion

Key Market Developments:

May 2023: SIGA Technologies’ Tecovirimat received expanded access protocol approval for use in monkeypox treatment in Europe.

Feb 2024: Bavarian Nordic initiated trials on a combined antiviral and vaccine strategy for orthopoxvirus containment.

Jan 2025: Tonix Pharmaceuticals announced a new antiviral candidate with dual activity against smallpox and monkeypox, entering Phase I trials.

FAQs:

1) What is the current market size of the Global Poxviridae Infections Drug Market?

The market was valued at USD 1.1 billion in 2023.

2) What is the major growth driver of the Global Poxviridae Infections Drug Market?

Key growth drivers include rising monkeypox cases and increased biodefense investments in antiviral stockpiling.

3) Which is the largest region during the forecast period in the Global Poxviridae Infections Drug Market?

North America held the largest share in 2023, while Asia-Pacific is expected to witness the fastest growth.

4) Which segment accounted for the largest market share in Global Poxviridae Infections Drug Market?

The Antiviral Drugs segment accounted for the largest share in 2023.

5) Who are the key market players in the Global Poxviridae Infections Drug Market?

Major players include SIGA Technologies, Chimerix, Emergent BioSolutions, Tonix Pharmaceuticals, and Bavarian Nordic.

Let me know if you'd like a formatted PDF version or additional visual elements like graphs or charts.